Fosaprepitant Dimeglumine

Form: Injection (IV)

Strength: 150 mg/vial

Reference Brands: Emend® IV (EU & US)

Category: Oncology Cancer Care

Fosaprepitant Dimeglumine is a trusted NK1 receptor antagonist used in oncology supportive care to prevent chemotherapy-induced nausea and vomiting (CINV). Available as a 150 mg intravenous injection, Fosaprepitant is commonly co-administered with 5-HT3 antagonists and corticosteroids. It enhances patient comfort and compliance during highly or moderately emetogenic chemotherapy. Approved in both the US and EU, and marketed under Emend® IV and as generics, it is widely used in hospital oncology departments and pharma B2B distribution. Reliable and effective, Fosaprepitant plays a critical role in managing CINV, improving quality of life for cancer patients receiving chemotherapy.